4-(2,2,2-trifluoroethyl)benzonitrile

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-(2,2,2-trifluoroethyl)benzonitrile
• 化学式: C₉H₆F₃N
• 分子量: 185.149
• InChiKey: XSAZEIMNUJYLOM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  23.8
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-(2,2,2-trifluoroethyl)benzonitrile 在 硼烷四氢呋喃络合物 、 N,N-二异丙基乙胺 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 为溶剂， 反应 54.0h， 生成 3-oxo-2-(2-(pyridin-2-yl)ethyl)-N-(4-(2,2,2-trifluoroethyl)benzyl)isoindoline-1-carboxamide
  参考文献：
  名称：

  3-Oxoisoindoline-1-carboxamides: Potent, State-Dependent Blockers of Voltage-Gated Sodium Channel Na_V1.7 with Efficacy in Rat Pain Models

  摘要：

  The voltage-gated sodium channel Na(V)1.7 is believed to be a critical mediator of pain sensation based on clinical genetic studies and pharmacological results. Clinical utility of nonselective sodium channel blockers is limited due to serious adverse drug effects. Here, we present the optimization, structure activity relationships, and in vitro and in vivo characterization of a novel series of Na(V)1.7 inhibitors based on the oxoisoindoline core. Extensive studies with focus on optimization of Na(V)1.7 potency, selectivity over Na(V)1.5, and metabolic stability properties produced several interesting oxoisoindoline carboxamides (16A, 26B, 28, 51, 60, and 62) that were further characterized. The oxoisoindoline carboxamides interacted with the local anesthetics binding site. In spite of this, several compounds showed functional selectivity versus Na(V)1.5 of more than 100-fold. This appeared to be a combination of subtype and state-dependent selectivity. Compound 28 showed concentration-dependent inhibition of nerve injury-induced ectopic in an ex vivo DRG preparation from SNL rats. Compounds 16A and 26B demonstrated concentration-dependent efficacy in preclinical behavioral pain models. The oxoisoindoline carboxamides series described here may be valuable for further investigations for pain therapeutics.

  DOI：

  10.1021/jm300623u
• 作为产物：
  描述：

  4-(羟甲基)苯甲腈 在 咪唑 、 铜 、 sodium hydride 作用下， 以 四氢呋喃 、 乙腈 、 mineral oil 为溶剂， 反应 9.5h， 生成 4-(2,2,2-trifluoroethyl)benzonitrile
  参考文献：
  名称：

  铜介导的黄原酸酯的脱氧三氟甲基化：C ？的生成 基于O的亲电试剂的CF3键

  摘要：

  将基于醇的官能团转化为三氟甲基类似物是一种理想的转化方法。但是，很少有方法能够将基于O的亲电试剂转化为三氟甲烷。使用梅本试剂作为CF的源苄黄原酸酯的铜介导的三氟甲基化3形成C  CF 3个键进行说明。该方法与带有有用官能团的苄基黄原酸酯的阵列兼容。初步机械调查表明，在C  CF 3原位成键的形式通过所述衬底的反应与产生CuCF 3和CuOTf。进一步的证据表明该反应可以通过自由基阳离子中间体进行。

  DOI：

  10.1002/chem.201302328

文献信息

• Denitrogenative Hydrotrifluoromethylation of Benzaldehyde Hydrazones: Synthesis of (2,2,2‐Trifluoroethyl)arenes
  作者：Zhensheng Zhao、Kevin C. Y. Ma、Claude Y. Legault、Graham K. Murphy

  DOI：10.1002/chem.201902818

  日期：——

  hydrazones of arylaldehydes with Togni's CF3 -benziodoxolone reagent, in the presence of potassium hydroxide and cesium fluoride, induces a denitrogenative hydrotrifluoromethylation event to produce (2,2,2-trifluoroethyl)arenes. This novel reaction was tolerant to many electronically-diverse functional groups and substitution patterns, as well as naphthyl- and heteroaryl-derived substrates. Advantages of this

  在氢氧化钾和氟化铯的存在下，芳基醛的azo与Togni的CF3-苯并恶唑酮试剂反应，会引发脱氮加氢三氟甲基化反应，从而生成（2,2,2-三氟乙基）芳烃。这种新颖的反应可耐受许多电子多样性的官能团和取代方式，以及萘基和杂芳基衍生的底物。该方法的优点包括容易大规模获得speed前体，速度和操作简便性，并且不含过渡金属。
• [EN] ISOINDOLINE DERIVATIVES COMPRISING PHENYL GROUPS AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS<br/>[FR] DÉRIVÉS ISOINDOLINE COMPRENANT DES GROUPES PHÉNYLES ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DE LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2009145721A1

  公开（公告）日：2009-12-03

  Compounds of formula I are claimed, (I) wherein R1 is hydrogen, C1-3alkyl, Ci_3alkoxy, cyano, hydroxy or halo; and wherein said Ci^alkyl is optionally substituted by one or more substituents independently selected from hydroxy, Ci^alkoxy andfluoro; and said Ci^alkoxy is optionally substituted by one or morefluoro; m is 1 or 2; R2 and R3 is each and independently selected from hydrogen, Ci_4haloalkyl, Ci_4haloalkoxy, halo, Ci_4alkoxy, Ci_4alkyl and C3_7cycloalkyloxy; wherein said C3. γcycloalkyloxy is optionally substituted by one or morefluoro; and R2 and R3 may not both be hydrogen; D is C3_7cycloalkyl or C3_7heterocycloalkyl; and wherein said Cs-jcycloalkyl or Cs- γheterocycloalkyl may optionally be substituted by one or more X*; X4 is halo, Ci_3alkyl, Ci_3alkyl0Ci_3alkyl, Ci_3alkoxy, benzyl, Ci_4alkylsulfonyl, oxo, R4O(C=O), R5(C=O), or C5.6 heteroaryl; wherein said Cisalkyl, CisalkylOCisalkyl, Ci^alkoxy and C i^alkylsulfonyl is optionally substituted by one or more fluoro; R4 is Ci_4alkyl, Ci_4alkyl0Ci_4alkyl, C5_6cycloalkyl, or aryl; R5 is Ci_4alkyl, Ci_4fluoroalkyl or Cs_6 heteroaryl; Li is Ci_4alkylene or a bond; L2 is Ci_3alkylene; with the exception of the compound 2-(cyclohexylmethyl)-3-oxo-N-[2-(trifluoromethyl)benzyl]isoindoline-l-carboxamide; as well as a pharmaceutically acceptable salt, or isomer thereof, or a salt of said isomer. The compounds of the invention are useful in therapy such as pain therapy.

  公式I的化合物被要求，其中R1是氢，C1-3烷基，Ci_3烷氧基，氰基，羟基或卤素基；其中所述Ci^烷基可以选择性地被一个或多个取代基独立地选择自羟基，Ci^烷氧基和氟基；所述Ci^烷氧基可以选择性地被一个或多个氟基取代；m为1或2；R2和R3分别且独立地选择自氢，Ci_4卤代烷基，Ci_4卤代烷氧基，卤素，Ci_4烷氧基，Ci_4烷基和C3_7环烷氧基；其中所述C3. γ环烷氧基可以选择性地被一个或多个氟基取代；且R2和R3不能同时为氢；D为C3_7环烷基或C3_7杂环烷基；其中所述Cs-j环烷基或Cs-γ杂环烷基可以选择性地被一个或多个X*取代；X4为卤素，Ci_3烷基，Ci_3烷基0Ci_3烷基，Ci_3烷氧基，苄基，Ci_4烷基磺酰基，氧代，R4O(C=O)，R5(C=O)，或C5.6杂环烷基；其中所述Ci烷基，Ci烷基0Ci烷基，Ci^烷氧基和Ci^烷基磺酰基可以选择性地被一个或多个氟基取代；R4为Ci_4烷基，Ci_4烷基0Ci_4烷基，C5_6环烷基，或芳基；R5为Ci_4烷基，Ci_4氟烷基或Cs_6杂环烷基；Li为Ci_4烷基或键；L2为Ci_3烷基；除了化合物2-(环己基甲基)-3-氧代-N-[2-(三氟甲基)苄基]异吲哚啉-1-羧酰胺；以及其药学上可接受的盐，或其异构体的盐。本发明的化合物在治疗中如疼痛治疗中是有用的。
• [EN] ISOINDOLINE DERIVATIVES COMPRISING AN ADDITIONAL HETEROCYCLIC GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS<br/>[FR] DÉRIVÉS ISOINDOLINE COMPRENANT UN GROUPE HÉTÉROCYCLIQUE SUPPLÉMENTAIRE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DE LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2009145718A1

  公开（公告）日：2009-12-03

  Compounds of formula I are claimed, wherein R1is hydrogen, C1_3alkyl, C1_3alkoxy, cyano, hydroxy or halo; wherein C1-3alkyl may optionally be substituted by one or more substituents independently selected from hydroxy, C1-3alkoxy orfluoro; and wherein Ci^alkoxy may optionally be substituted by one or more fluoro; m is 1 or 2; R2 and R3 is each and independently selected from hydrogen, Ci_4haloalkyl, C1_4haloalkoxy, halo, C1_4alkoxy, C1_4alkyl and C3_7cycloalkyloxy; and wherein said C3_7cycloalkyloxy may optionally be substituted by one or more fluoro; and whereas both R2 and R3 can not be hydrogen; Het is selected from any one of pyridinyl, pyrazinyl, isoxazolyl, pyrazolyl, indolyl, triazolyl and pyrimidinyl, wherein each such heteroaryl may optionally be substituted by one or more X4; X4 is halo, C1-3alkyl, C1-3alkyl0C1-3alkyl, -CH(CH3)-O-C(CH3)3,C1_4alkoxy, cyano, or hydroxyl, or Ci_2hydroxyalkyl;; and wherein said C1-3alkyl, C 1-3alkylOC1-3alkyl, -CH(CH3)-O-C(CH3)3, or C1_4alkoxy may each optionally be substituted by one or more fluoro; L1 is C1_4alkylene, which may optionally be fluorinated or hydroxylated; and L2 is C1-3alkylene; with the exception of the compounds: 2-[1-(1,5-dimethyl-lH-pyrazol-4-yl)ethyl]-5,7-dimethoxy-3-oxo-N-[2-(trifluoromethyl)benzyl]isoindoline-1-carboxamide; N-(4-fluorobenzyl)-3-oxo-2-(-pyridin-4-yletyl)isoindoline-1-carboxamide and N-(2-chlorobenzyl)-2[2-(1H-indol-3-yl)-1-methyletyl]-3-oxoisoindoline-1-carboxamide; The invention further relates to pharmaceutical compositions containing said compounds and to the use of said compounds in therapy.

  公式I的化合物被要求，其中R1是氢，C1-3烷基，C1-3烷氧基，氰基，羟基或卤素；其中C1-3烷基可以选择性地被一个或多个取代基取代，这些取代基独立地选自羟基，C1-3烷氧基或氟基；而C1-3烷氧基可以选择性地被一个或多个氟基取代；m为1或2；R2和R3分别且独立地选自氢，C1-4卤代烷基，C1-4卤代烷氧基，卤素，C1-4烷氧基，C1-4烷基和C3-7环烷氧基；其中所述的C3-7环烷氧基可以选择性地被一个或多个氟基取代；而且R2和R3都不能是氢；Het选自吡啶基，吡嗪基，异噁唑基，吡唑基，吲哚基，三唑基和嘧啶基中的任何一种，其中每种这样的杂环烷基可以选择性地被一个或多个X4取代；X4是卤素，C1-3烷基，C1-3烷氧基C1-3烷基，-CH(CH3)-O-C(CH3)3，C1-4烷氧基，氰基，或羟基，或C1-2羟基烷基；而所述的C1-3烷基，C1-3烷氧基C1-3烷基，-CH(CH3)-O-C(CH3)3，或C1-4烷氧基可以选择性地被一个或多个氟基取代；L1是C1-4烷基，可以选择性地被氟化或羟基化；而L2是C1-3烷基；除了以下化合物：2-[1-(1,5-二甲基-1H-吡唑-4-基)乙基]-5,7-二甲氧基-3-氧代-N-[2-(三氟甲基)苯甲基]异吲哚啉-1-羧酰胺；N-(4-氟苯甲基)-3-氧代-2-(-吡啶-4-基乙基)异吲哚啉-1-羧酰胺和N-(2-氯苯甲基)-2[2-(1H-吲哚-3-基)-1-甲基乙基]-3-氧代异吲哚啉-1-羧酰胺；本发明还涉及含有所述化合物的药物组合物以及所述化合物在治疗中的使用。
• [EN] ISOINDOLINE DERIVATIVES COMPRISING A CYANO GROUP AND THEIR USE IN THE TREATMENT OF PAIN DISORDERS<br/>[FR] DÉRIVÉS D'ISO-INDOLINE COMPRENANT UN GROUPE CYANO ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES DE LA DOULEUR
  申请人：ASTRAZENECA AB

  公开号：WO2009145719A1

  公开（公告）日：2009-12-03

  Compounds of formula I are claimed, wherein R1 is hydrogen, C1_3alkyl, C1_3alkoxy, cyano, hydroxy or halo; and wherein said C1-3alkyl is optionally substituted by one or more substituents independently selected from hydroxy, C1_3alkoxy andfluoro; and said C1_3alkoxy is optionally substituted by one or more fluoro; m is 1, 2 or 3; R2 and R3 is each and independently selected from hydrogen, C1-4haloalkyl, C1-4haloalkoxy, halo, C1-4alkoxy, C1-4alkyl and C3_7Cycloalkyloxy; wherein said C3_7cycloalkyloxy is optionally substituted by one or more fluoro; and R2 and R3 may not both be hydrogen; L1 is C1-4alkylene, pentylene, or C3-6 cycloalkylene, wherein said C1-4alkylene, pentylene or C3-6 cycloalkylene may be optionally substituted by one or more X4; X4 is fluoro, C1_3alkyl, C3_7Cycloalkyl, C1_3alkylOCi_3alkyl, C1_3alkoxy, cyano, hydroxy, R4O(C=O)-, R4NR5(C=O)-, R4O(C=O)NR5-, R4NR5(C=O)NR5-, R4(C=O)O-, R4(C=O)NR5-, R4NR5(C=O)O-, R4NR5(C=O)NR5-, C5-6 heteroaryl(C=O), or C5-6 heteroaryl; R4 is C1-4 alkylOC1-4 alkyl, C5-6 cycloalkyl, aryl, or aryl-C1-2 alkyl; R5 is H or methyl; and wherein said C1-3 alkylOC1-3alkyl, C1-3alkoxy and C1-4alkylsulfonyl is optionally substituted by one or more fluoro; L2 is C1-3 alkylene, optionally substituted by one or more X4; as well as pharmaceutically acceptable salt, or isomer thereof, or a salt of said isomer. Compounds of the invention are useful in therapy, such as pain therapy.

  公式I的化合物被声明，其中R1是氢，C1_3烷基，C1_3烷氧基，氰基，羟基或卤素; 其中所述的C1-3烷基可以选择地被一个或多个独立选择自羟基，C1_3烷氧基和氟代基的取代基所取代; 所述的C1_3烷氧基可以选择地被一个或多个氟代基所取代; m为1、2或3; R2和R3分别且独立地选择自氢，C1-4卤代烷基，C1-4卤代烷氧基，卤素，C1-4烷氧基，C1-4烷基和C3_7环烷氧基; 其中所述的C3_7环烷氧基可以选择地被一个或多个氟代基所取代; R2和R3不能同时为氢; L1为C1-4烷基，戊烷基或C3-6环烷基，其中所述的C1-4烷基，戊烷基或C3-6环烷基可以选择地被一个或多个X4所取代; X4为氟代基，C1_3烷基，C3_7环烷基，C1_3烷基氧C1_3烷基，C1_3烷氧基，氰基，羟基，R4O(C=O)-，R4NR5(C=O)-，R4O(C=O)NR5-，R4NR5(C=O)NR5-，R4(C=O)O-，R4(C=O)NR5-，R4NR5(C=O)O-，R4NR5(C=O)NR5-，C5-6杂环芳基(C=O)，或C5-6杂环芳基; R4为C1-4烷氧基C1-4烷基，C5-6环烷基，芳基，或芳基-C1-2烷基; R5为H或甲基; 其中所述的C1-3烷氧基C1-3烷基，C1-3烷氧基和C1-4烷基磺酰基可以选择地被一个或多个氟代基所取代; L2为C1-3烷基，可以选择地被一个或多个X4所取代; 以及药学上可接受的盐，或其异构体，或所述异构体的盐。本发明的化合物在治疗中很有用，如疼痛治疗。
• Iridacycles as Catalysts for the Autotandem Conversion of Nitriles into Amines by Hydrosilylation: Experimental Investigation and Scope
  作者：Mustapha Hamdaoui、Camille Desrousseaux、Houda Habbita、Jean-Pierre Djukic

  DOI：10.1021/acs.organomet.7b00749

  日期：2017.12.26

  heterolytic activation of the Si–H bond. The molecular structure of a new example of such an adduct was resolved by X-ray diffraction analysis. Theoretical considerations support a donor–acceptor [C,N}Cp*IrIII-H]→[SiEt3]+ (C,N} = benzo[h]quinolinyl) formulation where the cationic silyl moiety acting as a Z ligand binds both Ir and H centers. Under the conditions of the catalysis, the latter adduct is assumed

  合成了含有（五甲基环戊二烯基）铱（III）单元的一组iridacycles [C，N} Cp * Ir III -Cl]（C，N} =苯并[ h ]喹啉，二苯并[ f，h ]喹啉）并衍生为与BArF型阴离子缔合的阳离子[C，N} Cp * Ir-NCMe] +。后者的盐因其在H 2中对HSiEt 3的潜在催化性能而进行了基准测试-释放测试反应。表现最佳的BArF型盐显示出能够以低的催化负载量（大约）促进反应的能力。乙腈，丙腈和一系列芳腈底物的自动串联氢化硅烷化为0.5–1 mol％。机理研究证实，Si-H键的亲电和杂合活化可初步形成硅烷-铱环加合物。通过X射线衍射分析解析了这种加合物的新实例的分子结构。理论上的考虑支持了施主-受主[C，N} Cp * Ir III -H]→[SiEt 3 ] +（C，N} =苯并[ h ]喹啉基）的配方，其中阳离子甲硅烷基部分充当Z配体结合Ir和